Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 Janvier 2025 - 2:00PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced members of its management
team will present at the 43rd Annual J.P. Morgan Healthcare
Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT
(6:45pm ET).
The presentation will be available through a live webcast in the
investor relations section of Myriad’s website at
investor.myriad.com. An archived edition of the presentation will
be available later that day.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Myriad Genetics (NASDAQ:MYGN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
